Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01175980
Other study ID # NCI-2012-02981
Secondary ID NCI-2012-0298120
Status Completed
Phase Phase 2
First received
Last updated
Start date August 6, 2010
Est. completion date August 1, 2018

Study information

Verified date July 2020
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Description:

PRIMARY OBJECTIVES:

I. To evaluate the efficacy by means of response rate (based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of vorinostat in the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC).

SECONDARY OBJECTIVES:

I. To characterize the safety and tolerability of vorinostat in this patient population.

II. To assess the time to tumor response (TTR). III. To assess the response duration (RD). IV. To evaluate progression free survival (PFS). V. To assess overall survival (OS).

TERTIARY OBJECTIVES:

I. To assess the association between a metabolic response by positron emission tomography (PET)/computed tomography (CT) after one cycle of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria (RECIST).

II. To assess the association between a metabolic response by PET/CT after the first and second chemotherapy cycle and PFS.

III. To assess flow sort diploid, aneuploid, and tetraploid populations of tumor cells from formalin fixed, paraffin-embedded (FFPE) tissue blocks from patients who benefited from suberoylanilide hydroxamic acid (SAHA) therapy and from patients who did not demonstrate a durable benefit.

IV. Profile the genomes of each cell population using oligonucleotide comparative genomic hybridization (CGH) arrays.

V. Perform whole exome analysis of the sorted tumor population and matching germ line sample for each of the patients selected.

VI. To assess stable disease duration (SDD). VII. To assess the association between response to vorinostat treatment and RAD23 homolog B (HR23B) on tumor paraffin blocks.

VIII. Retrospectively compare volumetric density (viable tumor volume = VTV) with pre-determined RECIST of target lesions in cross sectioning imaging (CT/magnetic resonance [MR]) already obtained.

IX. Correlate VTV, RECIST and treatment response (partial response, stable disease, progressive disease and stable disease over 6 months).

OUTLINE:

Patients receive vorinostat orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up for 180 days.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 1, 2018
Est. primary completion date June 8, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have histologically or cytologically confirmed locally advanced, recurrent or metastatic adenoid cystic carcinoma

- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm by chest x-ray, as >= 10 mm with CT scan, or >= 10 mm with calipers by clinical exam; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)

- Patients must have locally advanced and/or recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy; any prior number of chemotherapy regimens is allowed; a minimum of at least 4 weeks since prior chemotherapy or radiation therapy should have elapsed, 6 weeks if the last regimen included carmustine (BCNU) or mitomycin C

- Life expectancy of greater than 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky >= 60%)

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin within normal institutional limits (WNL)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)

- Creatinine within normal institutional limits or

- Creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

- Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of vorinostat will be determined following review of their case by the principal investigator

- No other diagnosis of malignancy unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed >= 5 years previously and currently with no evidence of disease; however - if the patient has had a previously diagnosed stage I/II malignancy of another type, consideration for recruitment may be made by the Cancer Therapy Evaluation Program (CTEP) senior investigator after discussion with local principal investigator (PI) and patient's physician

- Confirmed availability of tumor tissue (either fresh or from paraffin block) from the primary tumor or metastatic site to be available to use on correlative studies

- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

- Ability to understand and the willingness to sign a written informed consent document

- If the patient's tumor can be easily accessed, a pre-treatment biopsy will be mandatory

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; more than 21 days from major surgery should have elapsed before the first dose of the study drug

- Patients may not be receiving any other investigational agents or have received vorinostat in the past; patients should not have taken valproic acid for at least 4 weeks prior to enrollment

- Inability to take oral medications on a continuous basis

- Patients with active brain metastases should be excluded from this clinical trial; patients with previous brain metastases will be eligible if condition is treated and stable for >= 1 month

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat

- Patient is unable or unwilling to abide by the study protocol and to cooperate fully with the investigator or designee

- Patient on current therapy with enzyme-inducing anticonvulsants

Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Adenoid Cystic
  • Recurrent Oral Cavity Adenoid Cystic Carcinoma
  • Recurrent Salivary Gland Carcinoma
  • Salivary Gland Adenoid Cystic Carcinoma
  • Salivary Gland Neoplasms
  • Stage III Major Salivary Gland Cancer AJCC v7
  • Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
  • Stage IVA Major Salivary Gland Cancer AJCC v7
  • Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
  • Stage IVB Major Salivary Gland Cancer AJCC v7
  • Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
  • Stage IVC Major Salivary Gland Cancer AJCC v7
  • Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
  • Tongue Carcinoma

Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Vorinostat
Given PO

Locations

Country Name City State
Canada University Health Network-Princess Margaret Hospital Toronto Ontario
United States National Institutes of Health Clinical Center Bethesda Maryland
United States Case Comprehensive Cancer Center Cleveland Ohio
United States Case Western Reserve University Cleveland Ohio
United States Cleveland Veterans Administration Cleveland Ohio
United States Wayne State University/Karmanos Cancer Institute Detroit Michigan
United States City of Hope Comprehensive Cancer Center Duarte California
United States Lake University Ireland Cancer Center Mentor Ohio
United States Yale University New Haven Connecticut
United States Memorial Sloan Kettering Cancer Center New York New York
United States Ireland Cancer Center at Firelands Regional Medical Center Sandusky Ohio
United States City of Hope South Pasadena South Pasadena California

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Metabolic Response by PET/CT Scan Will assess the association between a metabolic response by PET/CT after one course of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria. Will also assess the association between a metabolic response by PET/CT after the first and second chemotherapy courses and PFS. Up to 56 days
Other Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks Number of patients with Flow sort diploid populations of tumor cells from FFPE tissue blocks reported as a count of participants. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Other Number of Patients With Flow Sort Aneuploid Populations of Tumor Cells From FFPE Tissue Number of patients with Flow sort aneuploid populations of tumor cells from FFPE tissue. Reported as descriptive results. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Other Number of Patients With Flow Sort Tetraploid Populations of Tumor Cells From FFPE Tissue Number of patients with Flow sort tetraploid populations of tumor cells from FFPE tissue. Reported as descriptive results. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Other Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population. Genomic profile of each cell population using oligonucleotide CGH arrays. Reported as unique probes on the CGH array. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Other The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample Reported as descriptive results. The combined CGH array and exome data will be mined to identify genes and pathways that are targeted by select somatic events in each of the patient subsets. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Other Stable Disease Duration (SDD) SDD will be reported as descriptive results as a median point estimate and a 90% confidence interval (CI) estimate. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Other Expression Level of HR23B Exact logistic modeling investigation would yield a point and 90% CI estimate of the odds ratio for response. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Primary Objective Response According to RECIST 1.1 Criteria Objective (Best) response according to RECIST 1.1 criteria. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Secondary Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 Toxicity will be tabulated via frequency distributions, and also dichotomized to report the proportion (and percentage) of patients experiencing a specified level (e.g., grade 3-4) of toxicity. Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Secondary Time to Recurrence (TTR) TTR will be summarized descriptively, reporting N, median, mean, standard deviation, standard error (SE), minimum, maximum, and 90% CI for the mean calculated from the SE and asymptotic normal distribution theory. From the start of the treatment until the RECIST measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded, assessed up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Secondary Response Duration (RD) Median point estimate and full range will be documented, since only two patients achieved a response. From the time measurement criteria are met for CR or PR (whichever is first) until the first date that recurrence or progression is objectively documented, assessed up to 60 months after the last dose of vorinostat max. treatment duration= 24 months
Secondary Progression-free Survival (PFS) Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both median point estimate and 90% confidence interval (CI) estimate. From start of treatment to time of progression or death, whichever occurs first, assessed up to 60 months after the last dose of vorinostat maximum treatment duration= 24 months
Secondary Overall Survival (OS) Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both point and 90% CI estimates of various statistics of interest can be calculated (e.g., median, 6-month event-free rate, 12-month event-free rate, etc.). Statistical graphs of each K-M curve (with 90% CI lines) will be generated for visual display.
(One year survival rate will be given since OS median was not reached due to too few events)
From the start of treatment until death from any cause, duration for reported probability= 1 year; survival data collected for up to a total of 60 months
See also
  Status Clinical Trial Phase
Recruiting NCT05408845 - Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer Phase 2
Completed NCT02538510 - Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Phase 1/Phase 2
Completed NCT01256385 - Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Phase 2
Active, not recruiting NCT03146650 - Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer Phase 2
Completed NCT00859937 - Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Phase 2
Active, not recruiting NCT04576091 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Phase 1
Recruiting NCT04895735 - Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Phase 2
Completed NCT01604772 - Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Phase 2
Recruiting NCT05669664 - Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers Phase 2
Completed NCT00458978 - Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Phase 2
Completed NCT01254617 - Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Phase 1
Active, not recruiting NCT00588770 - Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 3
Active, not recruiting NCT00954226 - Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer Phase 1